WEST PHARMACEUTICAL SERVICES INC (WST)

This company (West Pharmaceutical Services) is a leading global manufacturer specializing in the design and production of technologically advanced, high-quality integrated containment and delivery systems for injectable drugs and healthcare products, serving leading biologic, generic, pharmaceutical, diagnostic, and medical device companies worldwide, with international sales accounting for 57.5% of 2024 net sales. The business is organized into two global segments: Proprietary Products, which offers elastomers and primary containment components (stoppers and seals for injectable packaging, syringe and cartridge components), drug delivery devices (including self-injection devices for at-home therapy delivery), integrated solutions, and analytical lab services, along with drug containment solutions such as Crystal Zenith (a cyclic olefin polymer used in vials, syringes, and cartridges) that address glass incompatibility and breakage issues, plus films, coatings, washing, vision inspection, and sterilization services—manufactured across facilities in North and South America, Europe, and Asia with affiliates in Mexico and Japan; and Contract-Manufactured Products, a fully integrated business focused on the design, manufacture, and automated assembly of complex devices primarily for pharmaceutical, diagnostic, and medical device customers, using technologies like multi-component molding, in-mold labeling, ultrasonic welding, clean room molding, and device assembly for surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems as well as consumer products, with manufacturing facilities in North America and Europe. The company relies on three basic raw materials—elastomers, aluminum, and plastic—often sourced from single-source suppliers due to regulatory constraints, and maintains significant inventory levels to mitigate supply chain risk.

Its intellectual property portfolio includes patents, trademarks, and licensed technology (notably from Daikyo), with over 170 utility and design patents issued globally in 2024. The company's top ten customers accounted for 43.4% of 2024 consolidated net sales, with one customer representing 12.3% ($356.4 million) across both segments; products are distributed primarily through its own sales force and distribution network. Competition varies by segment, ranging from specialized drug delivery and containment technology providers to regional and global contract assembly manufacturers, with differentiation based on quality, regulatory expertise, engineering capability, and global manufacturing scale.

The company invests in research and development through its own facilities and contract engineering services to advance drug containment components, delivery devices, and administration systems, and employed approximately 10,600 people globally as of December 31, 2024, with operations subject to regulation by agencies including the FDA, European Medicines Agency, and China's National Medical Products Administration.